Disease · MONDO_0005411
Comparisons in its trials16
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 16 of 16
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| A - NUC-1031 and Cisplatin vs B - Gemcitabine and Cisplatin: deaths from any cause | 188 of 388 | 135 of 385 | 773 | NCT04163900 | Trial comparisons |
| A - NUC-1031 and Cisplatin vs B - Gemcitabine and Cisplatin: serious adverse events | 175 of 383 | 126 of 378 | 761 | NCT04163900 | Trial comparisons |
| A - NUC-1031 and Cisplatin vs B - Gemcitabine and Cisplatin: Objective Response Rate (ORR) | 53 of 284 | 34 of 275 | 559 | NCT04163900 | Trial comparisons |
| Cohort I vs Cohort II: ORR by Investigator Assessment | 34 of 80 | 0 of 7 | 87 | NCT04466891 | Trial comparisons |
| Cohort I vs Cohort II: Confirmed Objective Response Rate (ORR) by Independent Central Review (ICR) | 33 of 80 | 0 of 7 | 87 | NCT04466891 | Trial comparisons |
| Cohort I vs Cohort II: DCR by Investigator Assessment | 54 of 80 | 1 of 7 | 87 | NCT04466891 | Trial comparisons |
| Cohort I vs Cohort II: Incidence of Laboratory Abnormalities | 37 of 80 | 7 of 7 | 87 | NCT04466891 | Trial comparisons |
| Cohort I vs Cohort II: deaths from any cause | 60 of 80 | 6 of 7 | 87 | NCT04466891 | Trial comparisons |
| Cohort I vs Cohort II: Disease Control Rate (DCR) by ICR | 55 of 80 | 3 of 7 | 87 | NCT04466891 | Trial comparisons |
| Cohort I vs Cohort II: serious adverse events | 43 of 80 | 3 of 7 | 87 | NCT04466891 | Trial comparisons |
| Arm A (Atezolizumab) vs Arm B (Atezolizumab, Cobimetinib): deaths from any cause | 35 of 43 | 35 of 43 | 86 | NCT03201458 | Trial comparisons |
| Arm A (Atezolizumab) vs Arm B (Atezolizumab, Cobimetinib): serious adverse events | 32 of 43 | 31 of 43 | 86 | NCT03201458 | Trial comparisons |
| Cohort I vs Cohort II: Incidence of Anti-drug Antibodies (ADAs) | 1 of 78 | 0 of 7 | 85 | NCT04466891 | Trial comparisons |
| High Dose vs Low Dose: deaths from any cause | 1 of 32 | 0 of 28 | 60 | NCT02392637 | Trial comparisons |
| High Dose vs Low Dose: serious adverse events | 5 of 32 | 1 of 28 | 60 | NCT02392637 | Trial comparisons |
| Trametinib vs Chemotherapy: serious adverse events | 13 of 23 | 1 of 20 | 43 | NCT02042443 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005411/comparisons